(b) In view of (a) above, does not arise.

(c) Details of demand estimates as well as of production in the organised sector, (to the extent monitored by the Department and made available by the companies) are given below:—

Name of drug	Production 1989-90	Demand estimates 1989-90
1. Piroxicam	0·65 MT	1·1 MT
2. Lorazepam	N.A.	0·214 MT

(d) As and when adequate indigenous production is estalished, appropriate action is taken to safeguard indigenous industry through the EXIM Policy, the tariff mechanism etc.

Form 2A of DPCO, 1987

660. SHRI H. HANUMANTHAPPA: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 743 given in the Rajya Sabha on 25th July, 1991 and state:

(a) whether it is a fact that under Form 2A of Drugs Price Control Order, 1987 it is obligatory for the producer to disclose the details in respect of price decontrolled formulations;

(b) if so, what is the break up and MAPE provided by the formulator of Fasigyn Tablets in Form 2A;

(c) whether it is a fact that poor people are being exploited by overcharging the price of this Tinidazole based formulations;

(d) if so ,what steps have been taken to bring down the price at reasonable level;

(e) whether it is a fact that 90 per cent of the market of finished medicines based on Tinidazole is controlled by M/s. Ffizer and Cadila; and

(f) if so, on what basis this drug was price decontrolled and what steps have been taken to rectify the same?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) Yes, Sir. To the extent available, information has been given in the Statement.

(c) and (d) It is always the endeavour of the Government to make available medicines to the ultimate users at reasonable prices. As and when any unusual price increases is noticed, Government intervenes.

(e) No, Sir.

(f) The inclusion/exclusion of bulk drugs under price control under DPCO, 1987 is mainly based on the recommendations made by the Kelkar Committee in its main as well as supplementary report.

Statement

	Rs./Pack	
	Fasigyn 500	Fasigyn D.S.
	25X4'S	2'S
(a) Material cost	47·85	1·53
(b) Conversion cost (as per norms)	0·90	0·03
(c) Packing Material cost	7·20	0·15
(d) Packing charges (as per norms)	0·80	0·06
(e) Ex-factory cost	56·75	1·79
(f) MAPE	115·99	5·11
(g) Excise duty	19·59	0·78
(h) Retail Price	192·33	7·68

Products of M/s. Crews

661. SHRI H. HANUMANTHAPPA: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 752 given in the Rajya Sabha on 25th July, 1991 and state:

(a) whether it is a fact that besides Combiflam M/s. Crews were producing number of price controlled formulation in 1984 when the company crossed the exemption limit of Rs. 50 lakhs in sales turn over:

(b) if so, names of such products and the price being charged for each product;

(c) whether it is a fact that this fact and applications submitted by the company for price approval, were kept by the former Assistance Development Commissioer (PI);

(d) if so, the details thereof and action taken thereon;

(e) whether Government have taken any steps to assess the benefit accrued to the company due to connivance of ADC (PI); and

(f) if so, the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) ad (b) To the extent information is available, M/s. Crews were producing Alcagal Tablets and Corelgin Tablets besides Combiflam when they crossed the exemption of Rs. 50 lacs.

(c) No, Sir.

(d) to (f) Do not arise.

Overcharging by M/s. Infar

662. SHRI H. HANUMANTHAPPA: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 753 given in the Rajya Sabha on 25th July, 1991 and state:

(a) whether it is a fact that the M/s. Infar has refused to provide the information and data asked by Government;

(b) since when the company has been selling the product without price approval;

(c) what was the price fixed suo-moto and what was the price being charged by the company;

(d) when the show cause notice was issued to the company and what was their response;

(e) whether Government have taken any action against the company under Essential Commodities Act; and